Feasibility study of docetaxel and nedaplatin for recurrent squamous cell carcinoma of the uterine cervix

Anticancer Research

Volumn 28, Issue 4 C, 2008, Pages 2385-2388

  Watanabe, Yoh ^a   Nakai, Hidekatsu ^a   Etoh, Tomomaro ^a   Kanemura, Kazumi ^a   Tsuji, Isao ^a   Ishizu, Ayako ^a   Hoshiai, Hiroshi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cervical cancer; Chemotherapy; Docetaxel; Feasibility; Nedaplatin

Indexed keywords

DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; NEDAPLATIN;

ADULT; AGED; ALLERGY; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SQUAMOUS CELL CARCINOMA; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA; VOMITING;

ADULT; AGED; AGRANULOCYTOSIS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKOPENIA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; TAXOIDS; UTERINE CERVICAL NEOPLASMS;

EID: 48849084175     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Omura GA, Blessing JA, Vaccarello L, Herman ML, Clarke-Pearson DL, Mutch DG and Anderson B: Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 15: 165-171, 1997.
2. Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS, Sood AK, Markman M and Benda J: Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 20: 1832-1837,2002.
3. Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, Miller DS, Olt G, King S, Boggess JF and Rocereto TF: Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 22: 3113-3119,2004.
4. Long HJ III, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA and Fiorica JV: Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 23: 4626-4633, 2005.
5. Monk BJ, Alberts DS, Burger RA, Fanta PT, Hallum AV III, Hatch KD and Salmon SE: In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers. Gynecol Oncol 71: 308-312, 1998.
6. Koshiyama M, Kinezaki M, Uchida T and Sumitomo M: Chemosensitivity testing of a novel platinum analog, nedaplatin (254-S), in human gynecological carcinomas: a comparison with cisplatin. Anticancer Res 25: 4499-4502, 2005.
7. Tsuda H, Hashiguchi Y, Nishimura S, Miyama M, Nakata S, Kawamura N and Negoro S: Phase I-II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer. Br J Cancer 91: 1032-1037, 2004.
8. Yoshioka T, Sakayori M, Kato S, Chiba N, Miyazaki S, Nemoto K, Shibata H, Shimodaira H, Ohtsuka K, Kakudo Y, Sakata Y and Ishioka C: Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation. Int J Clin Oncol 11: 454-460, 2006.
9. Kurita H, Yamamoto E, Nozaki S, Wada S, Furuta I and Kurashina K: Multicenter phase I trial of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma. Oral Oncol 40: 1000-1006, 2004.
10. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A and Kaye SB: Scottish Gynaecological Cancer Trials Group: Phase III randomized trial of docetaxel-carboplatin versus paclitaxel- carboplatin as firstline chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96: 1682-1691,2004.
11. Kudelka AP, Verschraegen CF, Levy T, Edwards CL, Fishman A, Freedman RS, Kaplan A, Kieback DG, Mante R, Ende K, Steger M and Kavanagh JJ: Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix. Anticancer Drugs 7: 398-401, 1996.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid cancers. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
13. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL III, Walker JL and Gersell D: Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340: 1154-1161, 1999.
14. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL and Insalaco S: Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340: 1144-1153, 1999.
15. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, Clarke-Pearson DL and Liao SY: Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 17: 1339-1348, 1999.
16. Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J, Rotman M, Gershenson D and Mutch DG: Pelvic irradiation with concurrent chemotherapy versus pelvic and paraaortic irradiation for high-risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90-01. J CHn Oncol 22: 872-880, 2004.
17. Peters WA III, Liu PY, Barren RJ II, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W Jr and Alberts DS: Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18: 1606-1613, 2000.
18. Brader KR, Morris M, Levenback C, Levy L, Lucas KR and Gershenson DM: Chemotherapy for cervical carcinoma: factors determining response and implications for clinical trial design. J Clin Oncol 16: 1879-1884, 1998.
19. Eralp Y, Saip P, Sakar B, Kucucuk S, Aydiner A, Dincer M, Aslay I and Topuz E: Prognostic factors and survival in patients with metastatic or recurrent carcinoma of the uterine cervix. Int J Gynecol Cancer 13: 497-504, 2003.
20. Garcia AA, Blessing JA, Vaccarello L and Roman LD: Gynecologic Oncology Group Study: Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Am J Clin Oncol 30: 428-431,2007.